What did @clipnest96 actually say?
Tom Segura's podcast clip, reposted here, floats the idea that a peptide called "sloop" (likely a phonetic mangling of "SLOPP" or a reference to SLU-PP-332) can "trick your body to think you exercise." The creator admits upfront they're working from a half-remembered article: "I don't know what it is. I read some article about it quite a while ago." Credit for the honesty. But 356,000 views later, that vague recollection has become a viral claim about an exercise-replacing pill.
The core assertion is that this compound, described as currently in "pill form," delivers the benefits of exercise through a single peptide or small molecule. No dosage, no mechanism, no timeline, no context about where this research actually stands. Just the headline.
Does the science back this up?
Partially, and with enormous caveats. The compound most likely being referenced is SLU-PP-332, a synthetic ERR (estrogen-related receptor) agonist studied in rodent models. It is not a peptide. And it is nowhere near human use.
A 2023 study by Skinner et al. published in the Journal of Medicinal Chemistry found that SLU-PP-332 activated ERRα, ERRβ, and ERRγ receptors in mice, mimicking some transcriptional signatures of aerobic exercise, particularly in skeletal muscle. Treated mice showed improved running endurance compared to sedentary controls. That's real. But "improved endurance in sedentary mice" and "replaces exercise for humans" are separated by a canyon of unfinished research. No human trials exist. The compound has not been tested for safety in humans. It has not been approved by any regulatory body.
A 2022 paper by Narkar and colleagues in Cell Metabolism established the theoretical foundation for ERR agonists as exercise mimetics, but explicitly framed this as a potential therapeutic tool for people physically unable to exercise, not as a biohack for healthy adults.
What did they get wrong (or right)?
They got the general direction right: exercise mimetic research is real and genuinely interesting. Researchers are working on compounds that activate some of the same molecular pathways as physical activity. That part isn't science fiction.
Here's what they got wrong, and it matters. First, SLU-PP-332 is not a peptide. It's a small molecule ERR agonist. Calling it a peptide is chemically incorrect, and in a category (peptide therapy) where terminology affects what people inject or ingest, that's not a minor slip. Second, it is not in pill form available to consumers. It exists in research-grade synthesis for laboratory use. Third, and most importantly, "trick your body to think you exercise" dramatically overstates what the science shows. ERR activation replicates some metabolic gene expression patterns. It does not replicate bone density adaptations, neurological benefits, cardiovascular structural changes, or the psychological effects of exercise. The claim flattens a complex, multi-system phenomenon into a single molecular switch.
What should you actually know?
Exercise mimetic research is a legitimate field, and some of it is promising for specific medical populations: people with heart failure, muscle-wasting diseases, or mobility limitations. That's the population researchers have in mind. A 2024 review by Auwerx and colleagues in Nature Metabolism outlined the therapeutic potential of metabolic pathway activators while noting that no compound has yet replicated the full systemic benefits of exercise in any mammal, let alone a human.
For healthy adults, the honest summary is this: there is no pill or peptide currently available that replicates exercise. There may never be one that does so completely, because exercise is not a single signal. It's a coordinated stress response across dozens of systems simultaneously.
If you're seeing this compound marketed as a consumer peptide product, that's a red flag. SLU-PP-332 has no human safety data. Sourcing research chemicals and self-administering them based on a TikTok clip is a genuinely bad idea.
- SLU-PP-332 is a research compound, not a consumer product
- No human clinical trials have been completed or registered for this compound
- ERR agonism replicates some, not all, exercise-related gene expression in mice
- The "pill form" framing implies availability that does not exist for consumers